Healthcare stocks face 2026 policy headwinds as capex rankings highlight sector differences

Healthcare stocks refer to companies within the healthcare sector that provide medical services, manufacture equipment or drugs, and offer health insurance. Historically, this sector is categorized as "defensive" because the demand for healthcare remains relatively inelastic regardless of economic cycles. As of January 2026, the sector has faced headwinds, with the Centers for Medicare and Medicaid Services indicating a net reimbursement increase of only 0.09% for 2027, significantly below the 7.2% rise in healthcare spending seen in 2024.

According to the Global Industry Classification Standard, the healthcare sector is divided into two primary groups: Healthcare Equipment & Services and Pharmaceuticals, Biotechnology & Life Sciences. The industry includes pharmaceuticals and biotechnology, medical devices and equipment, healthcare providers and services, and managed care and insurance.

Capital expenditures in healthcare carry very different meanings across subindustries within the sector. Hospital systems spend heavily on buildings, imaging equipment, and electronic health record platforms. Device and instrument makers fund manufacturing capacity and regulatory validation. Drug developers, whose largest investment is research rather than physical plant, run comparatively modest capex programs because their core asset is intellectual property protected by patents, not the factories that manufacture the product.

For providers and device makers, sustained capex funds capacity expansion and productivity improvements that translate into future revenue and margin. For drug developers, the more meaningful investment line is research and development, which is expensed immediately rather than capitalized. A capex ranking mixes these models and risks flattering capital-heavy providers while understating the innovation spend that actually drives value in the pharmaceutical and biotech side of the sector.

In the latest annual filings, the top healthcare companies ranked by capital expenditures were HCA Healthcare at $4.94B, Johnson & Johnson at $4.83B, Merck & Co. at $4.11B, UnitedHealth Group at $3.62B, and CVS Health at $2.83B. They were followed by AstraZeneca at $2.81B, Pfizer at $2.63B, Abbott Laboratories at $2.17B, and Medtronic and Amgen at $1.86B each.

Investing in health stocks typically offers a blend of stability and growth. The sector is driven by an aging global population and the prevalence of chronic diseases. Innovation, such as the rise of GLP-1 weight-loss drugs, acts as a significant catalyst for growth, while a single regulatory decision can significantly alter the valuation of biotechnology firms.

Government intervention remains the single largest risk factor for health stocks. Recent reports indicate that the U.S. administration is focused on lowering insurance premiums, with specific focus on Medicare Advantage reimbursement rates. The FDA approval process also remains a critical milestone, and the success or failure of a Phase 3 clinical trial can often determine the market cap of a mid-sized biotech firm overnight.

Investors often track the sector through ETFs such as the Health Care Select Sector SPDR Fund (XLV), while the iShares Biotechnology ETF (IBB) offers a focused approach to the biotech space. Investors typically evaluate these stocks using Price-to-Earnings (P/E) ratios, organic sales growth, and dividend yields.